Sign in
RGLS Stock Price, Chart, Stats & News
Regulus Therapeutics Inc.
Save
Regulus Therapeutics Inc. (RGLS) does not currently pay a dividend.
564.95M
Market cap
–
Current P/E
–
Forward P/E
RGLS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -77.06% |
Operating margin | -11615.88% |
Pretax margin | -10731.47% |
Net margin | -10731.47% |
Effective tax rate | – |
ROA | -48.76% |
ROE | -47.13% |
D/E | 0.02x |
Interest coverage ratio | -1128.40x |
RGLS valuation
P/E | – |
P/S | 1661.62x |
P/B | 7.82x |
P/CF | -16.92x |
P/FCF | -17.84x |
P/OCF | -16.92x |
PEG | -0.92x |
EV multiple | -16.94x |
About
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition.
Similar securities
Based on sector and market capitalization
Report issue